Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb 2Q

Revenues were up 8% excluding foreign exchange impact. Biopharmaceutical sales were $4.7 billion in the quarter (+4%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb 2Q

2Q Revenues: $5.4 billion (+3%)

2Q Earnings: $1.3 billion (+29%)

YTD Revenues: $10.4 million (+3%)

YTD Earnings: $2.2 billion (+17%)

Comments: Revenues were up 8% excluding foreign exchange impact. Biopharmaceutical sales were $4.7 billion in the quarter (+4%). Plavix sales were $1.5 billion (+11%). Abilify sales were $643 million (+22%). Baraclude sales were $179 million (+32%). Sustiva franchise sales were $312 million (+11%). Reyataz sales were $331 million (+2%). Orencia and Sprycel sales were up 40% and 41% to $148 million and $107 million, respectively. Erbitux sales were down 12% to $173 million. R&D expenses were flat at $781 million in the quarter.

View BMS in Contract Pharma’s Top Companies Report:
http://contractpharma.com/articles/2009/07/bristolmyers-squibb

Sign up today for Contracting & Outsourcing 2009!
stagging_cp.rodpub.com/2009conference


Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters